Search results
Diabetic ketoacidosis (DKA) is a frequent and potentially life-threatening complication of type 1 diabetes. Though preventable and despite advances in monitoring technologies, insulin therapeutics and insulin delivery systems, the rates of both community and hospital acquired DKA remain largely unchanged. Although mortality today is relatively
DIABETIC KETOACIDOSIS – INITIAL MANAGEMENT GUIDE. DIAGNOSIS OF DKA BLOOD GLUCOSE(BG) > 11*- (glucose may be normal in a known diabetic) + ACIDOSIS - pH <7.3 or HCO3-<15mmol/l + KETONAEMIA – Bld Ketones> 3mmol/l.
Add Dextrose (D51⁄2NS or D5NS*) to IVF @ 150 – 250 mL/h to maintain serum glucose 150 – 200 mg/dL and continue insulin at same rate. Titrate insulin to a minimum 0.1 Units/kg/hr and glucose goal between 150 – 200 mg/dL until ketosis and anion gap resolves.
22 maj 2020 · MONTEFIORE SUBCUTANEOUS INSULIN DKA PROTOCOL. This is a subcutaneous (SubQ) insulin protocol that replaces insulin drip needs for mild to moderate DKA. Procedures are adapted for COVID-related considerations of minimizing risk to staff while optimizing patient safety and health.
Diabetic ketoacidosis (DKA) is a life-threatening complication of diabetes. DKA occurs due to absolute or relative insulin deficiency, accompanied by excessive counter-regulatory hormone secretion (adrenaline, cortisol, glucagon). This results in excessive lipolysis with release of free fatty acids which are metabolised to ketoacids.
1.1 This document sets out the University Hospitals of Leicester (UHL) guidelines for the management of Diabetic Ketoacidosis (DKA) in adults. It is based on the Joint British Diabetes Societies (JBDS) guideline ‘The Management of Diabetic Ketoacidosis in Adults’ (Revised June 2021).
The protocol aims to safely treat eligible DKA patients with subcutaneous insulin to minimize COVID-19 risks compared to intravenous insulin drips. This document presents a subcutaneous insulin protocol for treating mild to moderate diabetic ketoacidosis (DKA) developed by Montefiore hospital.
